Only a few days to go: We’re raising £25,000 to keep TheyWorkForYou running and make sure people across the UK can hold their elected representatives to account.

Donate to our crowdfunder

Health: Drugs Pricing

House of Lords written question – answered on 10th July 2013.

Alert me about debates like this

Photo of Lord Clement-Jones Lord Clement-Jones Liberal Democrat

To ask Her Majesty’s Government, further to the Written Answer by Earl Howe on 24 June (WA 93), why they do not envisage that all cancer drugs previously considered but not recommended by the National Institute for Health and Care Excellence will be assessed under value-based pricing.

Photo of Earl Howe Earl Howe The Parliamentary Under-Secretary of State for Health

The vast majority of branded medicines already on the market before 2014 will be covered by the successor arrangements to the current Pharmaceutical Price Regulation Scheme. This is in line with the proposals set out in the consultation, A new value-based approach to the pricing of branded medicines, which ran from December 2010 to March 2011, and the Government’s response, published in July 2011. We are, however, still considering the possibility of a small number of existing drugs being assessed under value-based pricing on a case-by-case basis.

The National Institute for Health and Care Excellence will continue to keep its published guidance under review in order to take account of the latest available evidence.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.